

Име и презиме	<b>Наташа Ђорђевић</b>		
Звање	Редовни професор		
Назив институције у којој наставник ради са пуним радним временом и од када	Факултет медицинских наука, Универзитет у Крагујевцу		2004.
Ужа научна односно уметничка област	Фармакологија и токсикологија		
Академска каријера			
	Година	Институција	Област
Избор у звање	2018.	Факултет медицинских наука, Универзитет у Крагујевцу	Фармакологија и токсикологија
Докторат	2008.	Медицински факултет, Универзитет у Крагујевцу	Медицина
Специјализација	2013.	Факултет медицинских наука, Универзитет у Крагујевцу	Клиничка фармакологија
Магистратура	2003.	Медицински факултет, Универзитет у Крагујевцу	Медицина
Диплома	2000.	Медицински факултет, Универзитет у Крагујевцу	Медицина
Репрезентативне референце			
1.	Djordjevic N, Radmanovic B, Cukic J, Baskic D, Djukic-Dejanovic S, Milovanovic D, Aklillu E. Cigarette smoking and heavy coffee consumption affecting response to olanzapine: the role of genetic polymorphism. <i>World J Biol Psychiatry</i> . 2018; doi: 10.1080/15622975.2018.1548779.		
2.	Jurišić V, Obradovic J, Pavlović S, Djordjevic N. Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. <i>Anal Cell Pathol (Amst)</i> . 2018;2018:6192187.		
3.	Radosavljevic I, Stojanovic B, Spasic M, Jankovic S, Djordjevic N. CFTR IVS8 Poly-T Variation Affects Severity of Acute Pancreatitis in Women. <i>J Gastrointest Surg</i> . 2018. doi: 10.1007/s11605-018-3913-8.		
4.	Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, Djordjevic N. N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians. <i>Eur J Clin Pharmacol</i> . 2018;74(7):903-911.		
5.	Radmanovic B, Djukic-Dejanovic S, Milovanovic DR, Djordjevic N. Cigarette smoking and heavy coffee drinking affect therapeutic response to olanzapine. <i>Srp Arh Celok Lek</i> . 2018;146(1-2):43-7.		
6.	Mugosa S, Djordjevic N, Djukanovic N, Protic D, Bukumiric Z, Radosavljevic I, Boskovic A, Todorovic Z. Factors affecting the development of adverse drug reactions to $\beta$ -blockers in hospitalized cardiac patient population. <i>Patient Prefer Adher</i> . 2016;10:1461-9.		
7.	Obradovic J, Djordjevic N, Tosic N, Mrdjanovic J, Stankovic B, Stanic J, Zaric B, Perin B, Pavlovic S, Jurisic V. Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study. <i>Tumor Biol</i> . 2016;37(8):10479-86.		
8.	Mugosa S, Djordjevic N, Bukumiric Z, Djukanovic N, Cukic J, Radosavljevic I, Baskic D, Protic D, Zdravkovic M, Todorovic Z. PREDICT score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients. <i>Clin Exp Pharmacol Physiol</i> . 2016;43(3):379-81.		
9.	Dagovic A, Matter Walstra K, Gutzwiller SF, Djordjevic N, Rankovic A, Djordjevic G, Kocic S, Vasiljevic D, Canovic P, Kovacevic A, Aleksandar D, Dragojevic Simic V, Jakovljevic M, Schwenkglenks M. Resource use and costs of newly diagnosed cancer initial medical care. <i>Eur J Oncol</i> 2014;19(3):166-84.		
10.	Djordjevic N, Jankovic SM, Milovanovic JR. Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children. <i>Eur J Drug Metab Pharmacokinet</i> 2017;42(5):729-744.		
11.	Spasic M, Jankovic S, Stefanovic S, Kostic I, Radovanovic D, Đorđević N, Radosavljević I, Divjak A, Milojević A, Jelić I, Čanović D. Clinical And Laboratory Parameters Associated With Death In Acute Pancreatitis. <i>Vojnosanit Pregl</i> 2017; 74(9): 821–830.		
12.	Jurišić V, Obradović J, Tošić N, Pavlović S, Kulić M, Djordjević N. Effects of DMSO, glycerol, betaine and their combinations in detecting single nucleotide polymorphisms of epidermal growth factor receptor (EGFR) gene promoter sequence in non-small-cell lung cancer (NSCLC) patients. <i>J Pharm Biomed Anal</i> 2016;128:275-9.		
13.	Milovanovic DD, Milovanovic JR, Radovanovic M, Radosavljevic I, Obradovic S, Jankovic S, Milovanovic D, Djordjevic N. The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients. <i>Balkan J Med Genet</i> 2016;19(1):21-28.		
14.	Djordjevic N, Milovanovic DD, Radovanovic M, Radosavljevic I, Obradovic S, Jakovljevic M, Milovanovic D, Milovanovic JR, Jankovic S. CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy. <i>Eur J Clin Pharmacol</i> 2016;72(4):439-45.		
15.	Jakovljevic MB, Djordjevic N, Jurisevic M, Jankovic S. Evolution of the Serbian pharmaceutical market alongside socioeconomic transition. <i>Expert Rev Pharmacoecon Outcomes Res</i> 2015; 15(3):521-530.		
16.	Jakovljevic M, Jovanovic M, Rancic N, Vyssoki B, Djordjevic N. LAT Software Induced Savings on Medical Costs of Alcohol Addicts' Care - Results from a Matched-Pairs Case-Control Study. <i>PLoS One</i> 2014; 9(11):e111931		
17.	Aklillu E, Djordjevic N, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M. High CYP2A6 Enzyme Activity as Measured by a Caffeine Test and Unique Distribution of CYP2A6 Variant Alleles in Ethiopian Population. <i>OMICS: A Journal of Integrative Biology</i> 2014; 18(7):446-453		
18.	Obradovic J, Jurisic V, Tosic N, Mrdjanovic J, Perin B, Pavlovic S, Djordjevic N. Optimization of PCR conditions for amplification of GC-Rich EGFR promoter sequence. <i>J Clin Lab Anal</i> 2013; 27(6):487-493.		
19.	Jakovljevic M, Riegler A, Jovanovic M, Djordjevic N, Patek K, Lesch O, Walter H. Serbian and Austrian alcohol-dependent patients: a comparison of two samples regarding therapeutically relevant clinical features. <i>Alcohol and alcoholism</i> 2013; 48(4):505-508.		
20.	Jakovljevic B.M, Mijailovic D.Z, Popovska Jovicic D.B, Canovic S.P, Gajovic M.O, Jovanovic R.M, Petrovic S.D, Milovanovic Z.O, Djordjevic D.N. Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2a+Ribavirine treated Chronic Hepatitis C Patients. <i>Hepat Mon</i> 2013; 13(6): e6750.		
21.	Djordjevic N, Carrillo JA, van den Broek MPJ, Kishikawa J, Roh HK, Bertilsson L, Aklillu E. Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. <i>Drug Metab Pharmacokinet</i> 2013; 28(2):93-97		
22.	Djordjevic N, Carrillo JA, Roh HK, Karlsson S, Ueda N, Bertilsson L, Aklillu E. Comparison of N-Acetyltransferase-2 Enzyme Genotype-Phenotype and Xanthine Oxidase Enzyme Activity Between Swedes and Koreans. <i>J Clin Pharmacol</i> 2012; 52(10):1527-1534.		
23.	Djordjevic N, Bogojevic J, Kostic M. Alcohol consumption among adolescents in Kraljevo, Serbia. <i>Cent Eur J Med</i> 2011; 6(3): 363-371.		
24.	Djordjevic N, Carrillo JA, Ueda N, Gervasini G, Fukasawa T, Suda A, Jankovic S, Aklillu E. N-acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a white population. <i>J Clin Pharm</i> 2011; 51(7):994-1003.		
25.	Djordjevic N, Ghotbi R, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism. <i>Eur J Clin Pharmacol</i> 2010; 66(7):697-703.		
26.	Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E. In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. <i>Eur J Clin Pharmacol</i> 2010; 66(6):571-578.		
27.	Andjelic S, Djordjevic N. Out-of-hospital cardiopulmonary resuscitation in four Serbian university cities: outcome follow-up according to the "Utstein style". <i>Signa Vitae</i> 2010; 5(1):27-33.		
28.	Djordjevic N, Ghotbi R, Jankovic S, Bertilsson L, Aklillu E. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. <i>Eur J Clin Pharmacol</i> 2008; 64(4):381-385.		
29.	Djordjevic N. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, volume 116. Drinking coffee, mate, and very hot beverages. Lyon, France: IARC; 2018		

30.	Djordjevic N, Boccia S, Adany R. Editorial: Translation of genomic results into public health practice. <i>Front Public Health - Health Economics</i> 2018 May 25;6:156. doi: 10.3389/fpubh.2018.00156.
31.	Rancic N, Dragojevic-Simic V, Vavić N, Kovacevic A, Segrt Z, Djordjevic N. Economic evaluation of pharmacogenetic tests in patients subjected to renal transplantation: a review of literature. <i>Front Public Health - Health Economics</i> 2016. doi: 10.3389/fpubh.2016.00189
32.	Dragas Milovanovic D, Jakovljevic M, Scekcic M, Djordjevic N. Caffeine consumption patterns and determinants among adolescents in Serbia. <i>Int J Adolesc Med Health</i> . 2016; doi: 10.1515/ijamh-2016-0076.
33.	Praznik I, Spasic M, Radosavljevic I, Stojanovic B, Canovic D, Radovanovic D, Savovic Z, Vojinovic R, Babic Z, Djonovic N, Lukovic T, Lazarevic P, Djordjevic N, Kostic I, Jelic I, Petrovic J, Stojanovic S, Jurisevic M, Grubor I, Nikolic Lj, Vucicevic K, Artinovic V, Milojevic A, Kostic M, Stefanovic S, Jankovic S. Analysis of treatment-related factors affecting mortality in patients with severe necrotizing acute pancreatitis. <i>Acta facultatis medicae Naissensis</i> 2016;33(3):173-85.
34.	Radosavljevic I, Milojevic A, Miljkovic J, Divjak A, Jelic I, Artinovic V, Spasic M, Stojanovic B, Canovic P, Jankovic S, Djordjevic N. Lack of PRSS1 and SPINK1 polymorphism in Serbian acute pancreatitis patients. <i>Ser J Exp Clin Res</i> . 2015;16(3):201-6.
35.	Dragas Milovanovic D, Radosavljevic I, Radovanovic M, Milovanovic J, Obradovic S, Jankovic S, Milovanovic D, Djordjevic N. CYP3A5 polymorphism in Serbian pediatric epileptic patients on carbamazepine treatment. <i>Ser J Exp Clin Res</i> . 2015; 16 (2): 93-9.
36.	Radmanović B, Đukić-Dejanović S, Janjić V, Borovčanin M, Milovanović D, Đorđević N. Genetic polymorphism of metabolizing enzymes in clinical response to olanzapine treatment. <i>Engrami</i> . 2013; 35(3-4):53-61.
37.	Đorđević N, Janković S, Stepanović M, Milovanović DR. A report of a medication error: Drug incompatibility. <i>Medicinski časopis</i> 2013; 47(1):39-41.
38.	N. Djordjevic, S. Jankovic. Prescribing in general practice. <i>Medicinski časopis</i> 2008; 2:26-30.

Збирни подаци научне, односно уметничке и стручне активности наставника

Укупан број цитата	Science Citation Index, Web of Science		
	Scopus		
Укупан број радова са SCI или (SSCI) листе	<b>27</b>		
Тренутно учешће на пројектима	<b>4</b>	Домаћи	<b>4</b>
		Међународни	
Усавршавања	Pharmacogenomics/-genetics course, DIRAC, IUPHAR & EACPT, Helsingør, Denmark (26-29.08.2008.); Pharmacogenetics research, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden (02.09.2006 -15.09.2007.); 4th European Summer School in Clinical Pharmacology & Therapeutics, Vrsac, Serbia (16-0.09.2006.); Pharmacogenetics course, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden (02.12.2004 - 25.02.2005.)		
Други релевантни подаци			